title: In vitro studies during long-term oral administration of specific transfer factor.
abstract: 153 patients suffering from recurrent pathologies, i.e. viral infections (keratitis, keratouveitis, genital and labial herpes) uveitis, cystitis, and candidiasis were treated with in vitro produced transfer factor (TF) specific for HSV-1/2, CMV and Candida albicans. The cell-mediated immunity of seropositive patients to HSV-1/2 and/or CMV viruses was assessed using the leucocyte migration inhibition test (LMT) and lymphocyte stimulation test (LST) in presence of the corresponding antigens, and the frequency of positive tests before, during and after TF administration was studied. The data were stratified per type of test, antigen and the recipients' pathology, and statistically evaluated. For the LMT, a total of 960 tests were carried out for each antigen dilution, 3 different antigen dilutions were used per test. 240/960 tests (25.4%) were found positive during non-treatment or treatment with unspecific TF, whereas 147/346 tests (42.5%) were found positive when the antigen corresponding to the specificity of the TF administered to the patient was used (P < 0.001). When the data were stratified following pathology, a significant increased incidence of positive tests during specific treatment was also observed (0.0001 < P < 0.05). In the LST (1174 tests), a significant increase of thymidine uptake was observed in the absence of antigen (control cultures), during treatment with both specific and unspecific TF, but also in the presence of antigen and/or autologous serum during specific TF administration (P < 0.0001). TF administration also significantly increased the soluble HLA class I antigens level in 40 patients studied to this effect.
authors.affiliation: Immunodiagnosis and Immunotherapy Unit, S. Orsola Malpighi Hospital, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pizza
authors.forename: C
authors.initials: C
authors.lastname: De Vinci
authors.forename: V
authors.initials: V
authors.lastname: Fornarola
authors.forename: A
authors.initials: A
authors.lastname: Palareti
authors.forename: O
authors.initials: O
authors.lastname: Baricordi
authors.forename: D
authors.initials: D
authors.lastname: Viza
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002464:Cell Migration Inhibition; D002648:Child; D002675:Child, Preschool; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D012995:Solubility; D014165:Transfer Factor / Q000627:therapeutic use*; D014777:Virus Diseases / Q000276:immunology* / Q000628:therapy* / Q000821:virology
chemical_list: D006680:HLA Antigens; D014165:Transfer Factor